SEPNSepterna, Inc.
What is the market doing?
No clear lean: rangebound and insiders net selling (often routine).
Choppy, but holding above its 200-day average. Price is +25% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Moderately shorted, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How SEPN is trading
Septerna, Inc. is +144% over the past year while the S&P 500 is +18%: 126 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +25%
vs 200-day average · a clear uptrend
- RSI (14)
- 49
RSI (14) · neutral
- Below its 52-week high
- 20%
Below its 52-week high
Details›
- Last close2026-10-09
- $38.32
- 1 monthS&P 500 +2.7%
- +1.4%
- 1 yearS&P 500 +18%
- +144%
- vs 50-day average$39.24
- −2.4%
- 52-week high
- $48.13
- 52-week low
- $16.00
- Annualised volatility
- 90%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- −$63M
| Year | Return |
|---|---|
| 2026 (year to date) | +37% |
| 2025 | +22% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 2 | 0 of 2 | −21% |
| Feb | 2 | 1 of 2 | −19% |
| Mar | 2 | 0 of 2 | −14% |
| Apr | 2 | 1 of 2 | +9.5% |
| May | 2 | 2 of 2 | +30% |
| Jun | 2 | 2 of 2 | +14% |
| Jul | 2 | 1 of 2 | +8.0% |
| Aug | 2 | 1 of 2 | +4.8% |
| Sep | 2 | 2 of 2 | +29% |
| Oct | 2 | 1 of 2 | +3.7% |
| Nov | 2 | 2 of 2 | +26% |
| Dec | 2 | 0 of 2 | −6.7% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Biotechnology
The closest names by size in the same industry